Oxford’s Doug Altman Receives Lifetime Achievement Award
Altman has been instrumental in the development of “truly robust guidelines for the reporting of clinical trials and wider clinical research studies”.
Prof. Doug Altman, founding director of the Centre for Statistics in Medicine in Oxford, U.K. has received the 2015 BMJ Lifetime Achievement for his contribution to improving reporting of health research.
Altman has been instrumental in the development of “truly robust guidelines for the reporting of clinical trials and wider clinical research studies,” noted GSK’s Global Head of Epidemiology Dr. Andrew Roddam, who presented the award on behalf of the sponsors.
Dr Fiona Godlee, Editor-in-chief of the The BMJ, said Professor Altman “has done more than anyone else to encourage researchers to fully report what they actually did, warts and all, rather than letting the best be the enemy of the good or, worse, pretending that research is perfect.”
Click here for the full release about the BMJ award winners.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
